Alex Herrera, MD, Talks Results From the SWOG Trial

Alex Herrera, MD, of the City of Hope, discusses his 2023 American Society of Clinical Oncology Annual Meeting plenary session on SWOG S1826 data with Chadi Nabhan, MD, MBA, FACP.

The randomized study compared nivolumab plus doxorubicin, vinblastine, and dacarbazine (AVD) with brentuximab vedotin plus AVD in advanced stage classic Hodgkin lymphoma.

The study, which was the largest Hodgkin lymphoma study in National Clinical Trials Network history, showed that nivolumab plus AVD improved progression-free survival (PFS) over brentuximab vedotin plus AVD. The one-year PFS rate was 94% in patients who received nivolumab plus AVD, significantly higher than the one-year PFS rate of 86% in those who recieved brentuximab vedotin plus AVD with a median follow-up of 12.1 months (hazard ratio, 0.48; 99% CI 0.27-0.87, one-sided P=.0005).

Its results may be a “key step towards harmonizing the pediatric and adult treatment” of advanced stage classic Hodgkin lymphoma, according to Dr. Herrera and colleagues.